Song et al., 2006 - Google Patents
Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque modelsSong et al., 2006
View HTML- Document ID
- 15918586947990802302
- Author
- Song R
- Liu S
- Adams R
- Leong K
- Publication year
- Publication venue
- Journal of interferon & cytokine research
External Links
Snippet
Controlled release of granulocyte-macrophage colony-stimulating factor (GM-CSF) protein by albumin-heparin microparticles administered via intramuscular vaccination in conjunction with HIV DNA vaccines stimulated HIV Gag-specific immune responses. In the murine …
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor 0 title abstract description 72
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | DNA vaccines: recent developments and future possibilities | |
| Ljungberg et al. | Self-replicating alphavirus RNA vaccines | |
| Green et al. | Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d | |
| Liu | DNA vaccines: an historical perspective and view to the future | |
| Saade et al. | Technologies for enhanced efficacy of DNA vaccines | |
| Giri et al. | DNA vaccines against human immunodeficiency virus type 1 in the past decade | |
| Ramsay et al. | Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity | |
| Rezaei et al. | Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials | |
| ES2339762T3 (en) | VACCINE AGAINST HIV AND USE PROCEDURE. | |
| Knudsen et al. | Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen | |
| Song et al. | Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models | |
| Rao et al. | Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model | |
| Billaut-Mulot et al. | Interleukin-18 modulates immune responses induced by HIV-1 Nef DNA prime/protein boost vaccine | |
| Khalid et al. | The development of DNA vaccines against SARS-CoV-2 | |
| Larijani et al. | HIV-1 p24-nef DNA vaccine plus protein boost expands T-cell responses in BALB/c | |
| Ahmed et al. | Innate immunity in experimental SIV infection and vaccination | |
| Cristillo et al. | Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation | |
| Nimal et al. | Enhancement of immune responses to an HIV gp120 DNA vaccine by fusion to TNF alpha cDNA | |
| Leitner et al. | Nucleic acid for the treatment of cancer: genetic vaccines and DNA adjuvants | |
| Garmory et al. | DNA vaccines for biodefence | |
| Stevceva et al. | Mucosal HIV vaccines: where are we now? | |
| EP4174183A1 (en) | Fusion gene, recombinant novel coronavirus high-efficiency immune dna vaccine, construction method therefor and use thereof | |
| Goldoni et al. | Mucosal and systemic anti-GAG immunity induced by neonatal immunization with HIV LAMP/gag DNA vaccine in mice | |
| Pastori et al. | Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations | |
| Bagley et al. | Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun |